| NAP has no effect on spatial memory after short-term treatment in advanced stage Alzheimer's disease mouse model. | |
| | |
MedLine Citation:
|
PMID: 19664667 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
NAPVSIPQ (NAP) is a small, active fragment of activity-dependent neuroprotective protein that has neuroprotective and memory enhancing properties at very low concentrations. Previous research demonstrated that 1-2 weeks of treatment provided memory enhancing effects in normal middle-aged and cholinergically lesioned rats. Improvement in cognitive performance was shown in 12-month-old C57Bl6/J mice after 10 days of oral treatment with D-NAP and D-SALLRSIPA. Additionally, NAP-related cognitive benefits on spatial memory were observed in a 3xTg Alzheimer mouse model after 6 months of chronic administration at a moderate stage of disease. In this study, the potential memory enhancing effect of NAP was investigated using the APP23 transgenic mouse model for Alzheimer's disease. Twelve-month-old male heterozygous APP23 mice and their wild-type control littermates were intraperitoneally injected with 0.3 microg NAP/g body weight or with saline vehicle for 22 consecutive days. Cognitive performance training in the Morris Water Maze (MWM) started on day 8 of treatment. The internal validity of our study was demonstrated by the fact that the APP23 mice performed significantly worse in the MWM than wild-type animals. Treatment with NAP, however, did not exert any significant effects on MWM performance. Although we failed to show significant memory enhancing effects in this study, NAP might be a promising peptide for disease-modifying therapy in neurodegenerative disease, but short-term effects are probably not to be expected. Also, most likely, treatment should start in an early stage, i.e. before full-blown pathology is eminent, and the necessary treatment period should enclose several months. |
| | |
Authors:
|
A Van Dijck; D Van Dam; P P De Deyn |
Related Documents
:
|
20371377 - Alteration of working memory but not in anxiety or stress response in p300/cbp associat... 18706097 - Kihi-to, a herbal traditional medicine, improves abeta(25-35)-induced memory impairment... 15858837 - Mice lacking the adenosine a1 receptor have normal spatial learning and plasticity in t... 17179867 - Expression of p25 impairs contextual learning but not latent inhibition in mice. 22506977 - Control-display mapping in brain-computer interfaces. 15458587 - Relationship of local infarctions to cognitive and psychosocial impairments after aneur... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-08-05 |
Journal Detail:
|
Title: Peptides Volume: 30 ISSN: 1873-5169 ISO Abbreviation: Peptides Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-11-25 Completed Date: 2010-02-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8008690 Medline TA: Peptides Country: United States |
Other Details:
|
Languages: eng Pagination: 2480-2 Citation Subset: IM |
Affiliation:
|
Laboratory of Neurochemistry & Behavior, Institute Born-Bunge, Dept Biomedical Sciences, University of Antwerp, Belgium. Annemie.vandijck@ua.ac.be |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alzheimer Disease
/
drug therapy*,
pathology Animals Disease Models, Animal Male Memory / drug effects* Mice Neuroprotective Agents / pharmacology*, therapeutic use* Oligopeptides / pharmacology*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/NAPVSIPQ peptide; 0/Neuroprotective Agents; 0/Oligopeptides |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Skeletal contributions to plasma CNP forms: Evidence from regional sampling in growing lambs.
Next Document: Neuropeptide changes and neuroactive amino acids in CSF from humans and sheep with neuronal ceroid l...